Home > Insider Trading > Filing (0001654954-20-000270)

Filing Details

Accession Number:: 0001654954-20-000270
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-01-10 14:13:35
Reporting Period:: 2020-01-08

Accepted Time:: 2020-01-10 14:13:35
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1540159	Edesa Biotech Inc.	EDSA	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1702636	Lumira Capital Investment Management Inc.	141 Adelaide Street West Suite 770 Toronto A6 M5H 3L5		No	No	No	No
1778046	Peter Velden Der Van	C/O Edesa Biotech Inc. 100 Spy Court Markham A6 L3R 5H6		No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Shares	Acquisiton	2020-01-08	128,722	$3.20	1,833,066	No	4	P	Indirect	Held by Lumira Capital II, L.P.
Common Shares	Acquisiton	2020-01-08	11,903	$3.20	169,502	No	4	P	Indirect	Held by Lumira Capital II (International), L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	Held by Lumira Capital II, L.P.
No	4	P	Indirect	Held by Lumira Capital II (International), L.P.

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Shares	Common Share Warrants (Right to Buy)	Acquisiton	2020-01-08	96,542	$0.00	96,542	$4.80
Common Shares	Common Share Warrants (Right to Buy)	Acquisiton	2020-01-08	8,928	$0.00	8,928	$4.80
Common Shares	Common Share Warrants (Right to Buy)	Acquisiton	2020-01-08	64,362	$0.00	64,362	$4.00
Common Shares	Common Share Warrants (Right to Buy)	Acquisiton	2020-01-08	5,952	$0.00	5,952	$4.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
96,542	2020-07-08	2023-07-08	No	4	P	Indirect
8,928	2020-07-08	2023-07-08	No	4	P	Indirect
64,362	2020-07-08	2020-11-08	No	4	P	Indirect
5,952	2020-07-08	2020-11-08	No	4	P	Indirect

Footnotes

The reported securities are included within 128,722 Common Shares purchased by the reporting person for $3.20 per Common Share. Each Common Share includes the purchase of Class A Warrants to purchase 0.75 of a Common Share, and Class B Warrants to purchase 0.50 of a Common Share.
The reported securities are included within 11,903 Common Shares purchased by the reporting person for $3.20 per Common Share. Each Common Share includes the purchase of Class A Warrants to purchase 0.75 of a Common Share, and Class B Warrants to purchase 0.50 of a Common Share.
This Form 4 is jointly filed by (i) Lumira Capital II, L.P. ("LCII LP"), (ii) Lumira Capital II (International), L.P. ("LCII INT LP"), (iii) Lumira Capital GP, L.P., (iv) Lumira GP Inc., (v) Lumira GP Holdings Co., and (vi) Lumira Capital Investment Management Inc. Lumira Capital GP, L.P., the general partners of which are Lumira GP Inc. and Lumira GP Holdings Co., is the general partner of LCII LP and LCII INT LP, and each of LCII LP and LCII INT LP is managed by Lumira Capital Investment Management Inc. Mr. van der Velden is an executive officer of Lumira GP Inc., Lumira GP Holdings Co., and Lumira Capital Investment Management Inc. Each of Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Capital Investment Management Inc. and Mr. van der Velden may be deemed to beneficially own the shares held by LCII LP and LCII INT LP, but each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any.
Consists of Class A Warrants to purchase Common Shares. The Class A Warrants are exercisable beginning on July 8, 2020 and expire on July 8, 2023.
Consists of Class B Warrants to purchase Common Shares. The Class B Warrants are exercisable beginning on July 8, 2020 and expire on November 8, 2020.